Loading...

AXSM AXSOME THERAPEUTICS INC Product Launches 8-K Filing

XSM

XSM

AXSOME THERAPEUTICS INC

(AXSM)

2025 8-K

Show Summary

Show Summary

New Product Launches

New Product Launches

Settlement Agreement

Equity Offerings

Financial Statements

Patent Settlement

FDA Meeting Support

Financial Results

Patent Settlement

Financial Results

Loan Agreement Amendment

FDA Acknowledgment

Patent Litigation Dismissed

Earnings Report

Annual Meeting of Stockholders

Patent Litigation Settlement

Financial Results Announcement

Results of CRESCENDO survey...

Phase 3 Trial Initiation

Update of Corporate Present...

Financial Results Announcement

Financial Update

Investor Day Event

Financial Results Announcement

Appointment of Director

Earnings Report

Notice Letter for Generic V...

Sale of Common Stock

Underwriting Agreement

Appointment of New Independ...

Annual Meeting Approval of ...

Financial Results Announcement

Reaffirmation of Cash Flow ...

Earnings Reports

License Agreement with Atna...

Notice Letter for Generic V...

Loan Agreement Amendment

External Links:

On April 1, 2025, Axsome Therapeutics announced results from its Phase 3 trial of solriamfetol for treating major depressive disorder. The details are included in a press release attached as Exhibit 99.1.

AI Assistant

AXSOME THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.